Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-02
DOI
10.1007/s00432-019-03097-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells
- (2019) Anna Maria Cseh et al. Frontiers in Physiology
- PARP inhibition — opportunities in pancreatic cancer
- (2019) Shubham Pant et al. Nature Reviews Clinical Oncology
- False positive plasma genotyping due to clonal hematopoiesis
- (2018) Yuebi Hu et al. CLINICAL CANCER RESEARCH
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhancement of Radiation Effectiveness in Cervical Cancer Cells by Combining Ionizing Radiation with Hyperthermia and Molecular Targeting Agents
- (2018) Marloes IJff et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors
- (2018) Monica Mangoni et al. RADIATION RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer
- (2018) Sabrina Köcher et al. INTERNATIONAL JOURNAL OF CANCER
- Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
- (2018) Min Wu et al. International Journal of Nanomedicine
- Targeting therapy-resistant cancer stem cells by hyperthermia
- (2017) A. L. Oei et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation
- (2017) Carmen Klein et al. Radiation Oncology
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines
- (2017) Narasimha Kumar Karanam et al. Cell Death & Disease
- Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
- (2017) Pepijn M. Schoonen et al. Nature Communications
- Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
- (2017) Arlene L. Oei et al. Oncotarget
- Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
- (2017) Kedar Hastak et al. Oncotarget
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
- (2017) Florence Koeppel et al. PLoS One
- Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells
- (2016) Takahisa Hirai et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer
- (2016) Min Zhang et al. GYNECOLOGIC ONCOLOGY
- The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma
- (2016) Mette Hjortkjær et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality
- (2016) Yanyan Jiang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer
- (2016) Wang Hong et al. Journal of Cancer Research and Therapeutics
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
- (2016) Ying-Qing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
- (2016) Jun-Mei Yi et al. MOLECULAR CANCER THERAPEUTICS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors
- (2014) Jianyang Chen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
- (2014) Paulina Podszywalow-Bartnicka et al. CELL CYCLE
- Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?
- (2014) Pablo Martinez et al. LUNG CANCER
- TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes
- (2014) Liang Liu et al. MOLECULAR CANCER RESEARCH
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- BRCA2 Mutation Linked to Lung Cancer Risk
- (2014) Cancer Discovery
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- Predicting Enhanced Cell Killing through PARP Inhibition
- (2012) J. K. Horton et al. MOLECULAR CANCER RESEARCH
- The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest
- (2011) Dana L. Madison et al. DNA REPAIR
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line
- (2009) Marta Chevanne et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
- (2008) Christopher J. Lord et al. DNA REPAIR
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started